Advertisement
Canada markets close in 4 hours 33 minutes

  • S&P/TSX

    21,811.93
    +103.49 (+0.48%)
     

  • S&P 500

    4,992.07
    -19.05 (-0.38%)
     

  • DOW

    37,932.14
    +156.76 (+0.41%)
     

  • CAD/USD

    0.7280
    +0.0017 (+0.23%)
     

  • CRUDE OIL

    83.15
    +0.42 (+0.51%)
     

  • Bitcoin CAD

    88,529.74
    +1,070.16 (+1.22%)
     

  • CMC Crypto 200

    1,376.50
    +63.88 (+5.12%)
     

  • GOLD FUTURES

    2,410.40
    +12.40 (+0.52%)
     

  • RUSSELL 2000

    1,948.41
    +5.46 (+0.28%)
     

  • 10-Yr Bond

    4.6170
    -0.0300 (-0.65%)
     

  • NASDAQ

    15,427.20
    -174.30 (-1.12%)
     

  • VOLATILITY

    18.38
    +0.38 (+2.11%)
     

  • FTSE

    7,900.43
    +23.38 (+0.30%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6823
    +0.0002 (+0.03%)
     
MARKETS LIVE BLOG:

STOCKS TRADE MIXED AFTER ISRAEL STRIKE-FUELLED TUMBLE

Apple pulls WhatsApp and Threads from China App Store

TEVA or AKRX: Which Is the Better Value Stock Right Now?

Zacks Equity Research
Updated
Is (LXFR) Outperforming Other Industrial Products Stocks This Year?

Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Teva Pharmaceutical Industries Ltd. (TEVA) and Akorn (AKRX). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and estimate revisions, while our Style Scores work to identify stocks with specific traits.

Teva Pharmaceutical Industries Ltd. has a Zacks Rank of #2 (Buy), while Akorn has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that TEVA likely has seen a stronger improvement to its earnings outlook than AKRX has recently. But this is just one piece of the puzzle for value investors.

Value investors analyze a variety of traditional, tried-and-true metrics to help find companies that they believe are undervalued at their current share price levels.

ADVERTISEMENT

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

TEVA currently has a forward P/E ratio of 9.39, while AKRX has a forward P/E of 65.31. We also note that TEVA has a PEG ratio of 2.35. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. AKRX currently has a PEG ratio of 2.84.

Another notable valuation metric for TEVA is its P/B ratio of 1.50. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, AKRX has a P/B of 2.79.

Based on these metrics and many more, TEVA holds a Value grade of B, while AKRX has a Value grade of C.

TEVA has seen stronger estimate revision activity and sports more attractive valuation metrics than AKRX, so it seems like value investors will conclude that TEVA is the superior option right now.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Teva Pharmaceutical Industries Ltd. (TEVA) : Free Stock Analysis Report
 
Akorn, Inc. (AKRX) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.